TGF‑β1 induces CREB1‑mediated miR‑1290 upregulation to antagonize lung fibrosis via Napsin�A

Guan, Shu‐Hong; Wu, Yudi; Zhang, Qiudi; Zhou, Jun

doi:10.3892/ijmm.2020.4565

Cited by 10 publications

(10 citation statements)

References 36 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, miR-1290 was elevated in peripheral blood dendritic cells from chronic rhinosinusitis patients with nasal polyps [112] and in the duodenal mucosa of coeliac patients [113]. MiR-1290 expression was also higher in plasma from patients with pulmonary fibrosis and it was able to directly target Napsin A proteinase to modulate cell proliferation and TGF-β1-induced fibrosis [114]. On the other hand, miR-1290 expression was decreased in tissue samples from patients with oral submucous fibrosis compared with normal mucosa [115].…”

Section: The Role Of Mir-1290 In Non-neoplastic Diseasesmentioning

confidence: 99%

An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential

Guz

Jeleniewicz

Cybulski

2022

IJMS

View full text Add to dashboard Cite

For more than two decades, the view of the roles of non-coding RNAs (ncRNAs) has been radically changing. These RNA molecules that are transcribed from our genome do not have the capacity to encode proteins, but are critical regulators of gene expression at different levels. Our knowledge is constantly enriched by new reports revealing the role of these new molecular players in the development of many pathological conditions, including cancer. One of the ncRNA classes includes short RNA molecules called microRNAs (miRNAs), which are involved in the post-transcriptional control of gene expression affecting various cellular processes. The aberrant expression of miRNAs with oncogenic and tumor-suppressive function is associated with cancer initiation, promotion, malignant transformation, progression and metastasis. Oncogenic miRNAs, also known as oncomirs, mediate the downregulation of tumor-suppressor genes and their expression is upregulated in cancer. Nowadays, miRNAs show promising application in diagnosis, prediction, disease monitoring and therapy response. Our review presents a current view of the oncogenic role of miR-1290 with emphasis on its properties as a cancer biomarker in clinical medicine.

show abstract

Section: The Role Of Mir-1290 In Non-neoplastic Diseasesmentioning

confidence: 99%

An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential

Guz

Jeleniewicz

Cybulski

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Downregulation of Nap‐A is a hallmark of lung adenocarcinoma and pulmonary fibrosis 114 . Overexpression of miR‐1290 in A549 cells not only significantly induces cell proliferation but also by downregulation of Nap‐A increases the level of fibrosis marker proteins (Collagen I, α‑SMA, and TGF‑β1) 88 …”

Section: Potential Roles Of Mir‐1290 In Cancer Prognosis and Treatmen...mentioning

confidence: 99%

The potential role of miR‐1290 in cancer progression, diagnosis, prognosis, and treatment: An oncomiR or onco‐suppressor microRNA?

Kalhori

Soleimani

Arefian

et al. 2021

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cancer is one of the leading causes of death in humans because of the lack of early diagnosis, distant metastases, and the resistance to adjuvant therapies, including chemotherapy and radiotherapy. In addition to playing an essential role in tumor progression and development, microRNAs (miRNAs) can be used as a robust biomarker in the early detection of cancer. MiR‐1290 was discovered for the first time in human embryonic stem cells, and under typical physiological situations, plays an essential role in neuronal differentiation and neural stem cell proliferation. Its coding sequence is located at the 1p36.13 regions in the first intron of the aldehyde dehydrogenase 4 gene member A1. miR‐1290 is out of control in many cancers such as breast cancer, colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, lung cancer, pancreatic cancer, and plays a vital role in their development. Therefore, it is suggested that miR‐1290 can be considered as a potential diagnostic and therapeutic target in many cancers. In addition to the importance of miR‐1290 in the noninvasive diagnosis of various cancers, this systematic review study discussed the role of miR‐1290 in altering the expression of different genes involved in cancer development and chemo‐radiation resistance. Moreover, it considered the regulatory effect of natural products on miR‐1290 expression and the interaction of lncRNAs by miR‐1290.

show abstract

“…Since then, several studies have shown that Napsin A can also be expressed in other tumor types [7,11,12]. For example, immunohistochemical Napsin A positivity was found in 0%-52% of clear cell renal cell carcinomas [6,[13][14][15][16][17][18][19][20][21][22], 72%-97% of papillary renal cell carcinomas [6,13,14,[16][17][18][20][21][22], 0%-48% of thyroid tumors [10,11,16,18,19,23,24], 69%-100% of clear cell carcinomas of the ovary [7,19,[25][26][27][28][29][30][31][32] and 0%-9% of cholangiocarcinomas [12,19,33,34]. Partially conflicting results with respect to positivity rates between these studies may be due to the use of different antibodies, the use of different immunostaining protocols as well as different criteria to determine positivity in these studies.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, it was demonstrated that Napsin A is regulated by thyroid transcription factor 1 (TTF1), a diagnostic marker in lung cancer [ 3 ]. A recent study has shown that downregulation of Napsin A promotes TGF-ß induced cell proliferation in lung adenocarcinoma cells [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Napsin A Expression in Human Tumors and Normal Tissues

Weidemann

Böhle

Contreras³

et al. 2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Background: Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.Methods: To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.Results: Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (p ≤ 0.03).Conclusion: This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas.

show abstract

TGF‑β1 induces CREB1‑mediated miR‑1290 upregulation to antagonize lung fibrosis via Napsin�A

Cited by 10 publications

References 36 publications

An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential

An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential

The potential role of miR‐1290 in cancer progression, diagnosis, prognosis, and treatment: An oncomiR or onco‐suppressor microRNA?

Napsin A Expression in Human Tumors and Normal Tissues

Contact Info

Product

Resources

About